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Background: Congenital heart diseases (CHDs) usually refer to abnormalities in the structure and/or function of the
heart that arise before birth. GATA4 plays an important role in embryonic heart development, hence the aim of this
study was to find the association of GATA4 mutations with CHD among the south Indian CHD patients.
Method: GATA4 gene was sequenced in 100 CHD patients (ASD, VSD, TOF and SV) and 200 controls. Functional
significance of the observed GATA4 mutations was analyzed using PolyPhen, SIFT, PMut, Plink, Haploview, ESE finder
3.0 and CONSITE.
Results: We observed a total of 19 mutations, of which, one was in 5′ UTR, 10 in intronic regions, 3 in coding
regions and 5 in 3′ UTR. Of the above mutations, one was associated with Atrial Septal Defect (ASD), two were
found to be associated with Tetralogy of Fallot (TOF) and three (rs804280, rs4841587 and rs4841588) were strongly
associated with Ventricular Septal Defect (VSD). Interestingly, one promoter mutation (−490 to 100 bp) i.e., 620 C>T
(rs61277615, p-value = 0.008514), one splice junction mutation (G>A rs73203482; p-value = 9.6e-3, OR = 6.508) and
one intronic mutation rs4841587 (p-value = 4.6e-3, OR = 4.758) were the most significant findings of this study.
In silico analysis also proves that some of the mutations reported above are pathogenic.
Conclusion: The present study found that GATA4 genetic variations are associated with ASD, TOF and VSD in South
Indian patients. In silico analysis provides further evidence that some of the observed mutations are pathogenic.
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Congenital heart disease (CHD) usually refers to abnor-
malities in the structure and/or function of the heart
that arise before birth. It has been estimated that about
1% and 6-8% of the newborns are affected with CHD in
United States and worldwide, respectively [1]. Most of
the studies conducted earlier reported that CHD has
multi-factorial etiology, but recent studies indicate mono-
genic etiologies for a subset of CHDs [2-4]. Mutations in
genes encoding transcription factor were found to cause
nonsyndromic, human congenital heart disease. The knock-
out and transgenic mouse studies demonstrated that tran-
scription factors play an important role during heart
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unless otherwise stated.been reported to be involved in the murine heart develop-
ment [5]. GATA binding protein 4 (GATA4), NK2 homeo-
box 5 (NKX2.5), T-box 5 (TBX5), Zic family member 3
(ZIC3), myosin heavy chain 6 (MYH6) and NOTCH are
some of the transcription factors, which play crucial role
in heart development [6].
Several familial studies reported that mutations in
GATA4 may cause different kind of CHD i.e., atrial sep-
tal defect (ASD), ventricular septal defect (VSD), tetral-
ogy of fallot (TOF) and pulmonary stenosis (PS) [7-9].
Among all transcription factors, GATA4 is the most
studied gene in different populations [9-13]. GATA4 has
been mapped on 8p23.1 and has seven exons, which
code for 442 amino acids and act as zinc finger
transcription factor. GATA4 plays an important role in
embryonic heart development such as proliferation of
cardiomyocytes, endocardial cushion formation, devel-
opment of right ventricle and septation of the outflow
tract. GATA4 binds to the consensus sequence of thetral . This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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factors such as; NKX 2.5 and TBX5 [14]. Subsequent
studies have explained that TBX5, NKX2-5 and GATA4
interact during embryonic development and are involved
in the regulation of heart developmental processes [6,15,16].
GATA4 knockout mice produce phenotypes like ventral
morphogenesis and heart tube formation [5].
ASD and VSD are the commonest types of CHD and
account for 50% of all cases of CHD. If proper precau-
tionary measures are not taken, these defects result in
ventricular dilation and heart failure, and ultimately
cause a decrease in life expectancy [17,18]. VSD and
ASD are defects in the ventricular and atrial septum, the
wall dividing the left and right ventricles, and atrium of
the heart, respectively. TOF is a congenital heart defect,
which is classically understood to involve in four ana-
tomical abnormalities of the heart i.e. right ventricular
hypertrophy, ventricular septal defects, pulmonic sten-
osis (PS) and overriding aorta of the heart. ASD, VSD
and TOF are common form of congenital heart disease
(CHD) in India and other countries. Compared to other
familial CHDs, the prevalence of ASD and VSD is
significantly higher [19]. GATA4 has been identified as
causative factors of familial ASD and VSD, and found to
play a predominant role in the pathogenesis of both
atrial and ventricular septal defects [7,20,21]. However,
segregation of VSD and TOF with the GATA4 mutation
needs to be explored.
CHD is the leading cause of infant morbidity and mor-
tality in India. Congenital heart diseases are found in 8–
10 of every 1,000 live births [22] and nearly 1,80,000
children are born with CHD each year in India [23]. Of
these, nearly 60,000 to 90,000 suffer from critical CHD
requiring early intervention [23]. Because of higher rate
of consanguineous marriages, frequency of congenital
heart disease is very high in Andhra Pradesh state of
southern India, compared to rest of India [24]. In spite
of higher number of CHD in India, there are very few
studies to find a link between GATA4 mutation and
congenital heart disease. Only two studies with CHD
patients were conducted to find the association between
few selected GATA4 SNP with CHD, however, their data
was not significant [25,26]. Therefore, in the present
study we have sequenced the complete coding region
including exon-intron boundaries of GATA4 to elucidate
the role of GATA4 in the etiology of CHD in South Indian
patients.
Methods
Clinical evaluation of CHD
Babies (including pre-mature infants), who were attend-
ing Innova Children’s Heart Hospital, Hyderabad were
screened for CHD according to a pre-designed protocol,
that include 2D echocardiography, color doppler andECG. Of these different phenotypes, four different types
of CHDs were considered for the present investigation;
they are: atrial septal defect (ASD), ventricular septal defect
(VSD), tetralogy of fallot (TOF), and single ventricle (SV).
Patient and the control samples
A total of 100 patients, who fulfilled the criteria of CHD
were selected for the study. Two hundred individuals,
who had no CHD or family history of CHD or any heart
disease, were also included in this study as control. The
case samples (CHD) were drawn from Innova Children’s
Heart Hospital, Hyderabad; while ethnically matched
control samples were collected from Innova and other
hospital in Hyderabad. Informed written consent was
obtained from the parents of CHD patients and the con-
trol subjects prior to the collection of blood sample. In
addition, we also took consent for ‘publication of indi-
vidual patient data’ for all those individuals included in
the manuscript (i.e.. all of those indicated in the family
trees)”. All patient samples were collected from special-
ized hospital and they were belongs to same ethnic
group (Dravidian). This study was conducted with prior
approval of Institutional Ethical Committee of the Innova
Children’s Heart Hospital, Hyderabad (IEC/IRB No. 001/
2010) and IICT, Hyderabad.
DNA isolation and sequencing
We collected about 2.0 ml of peripheral blood samples
from all the patients and controls in EDTA-coated vacutai-
ner and genomic DNA was isolated according to the proto-
col of Sambrook et al. 1989 [27]. GATA4 sequence from
the ENSEMBL (ID: ENSG00000136574; www.ensembl.org)
was used to design primer employing primer 3 software
(http://frodo.wi.mit.edu/) and was synthesized commer-
cially (Eurofins, India). Detailed sequences of all primers
used in this study have been summarized in Additional
file 1: Table S1. The amplification reactions contained
40 ng of DNA, 10 mM dNTP mix, 10X PCR buffer, 2 U of
Taq polymerase (Takara, catalogue no:R001B) and 5 pM
of both the primers. PCRs were carried out using ABI
GeneAmp PCR System 9700 (Forster city, USA). Amplifi-
cation conditions used were as follows; an initial dena-
turation at 95°C for 5 min., followed by 35 cycles of
denaturartion at 94°C for 1 min, annealing at 55-64°C for
30 sec (Additional file 1: Table S1) and at 72°C for 1 min.
A final extension was carried out at 72°C for 10 min.
PCR products were cleaned up using Exo-SAP-IT (USB,
Affymetrix, USA) and 1.0 μl of the purified products were
directly used as templates for sequencing using di-deoxy
chain terminator cycle sequencing protocol (BigDye
V3.1, Applied Biosystems, Forster city, USA) [28]. The
extended products were purified by ethanol precipitation
and run in an ABI 3730 Automated DNA Analyzer
(Applied Biosystems, Forster city, USA). Sequencing was
Table 1 Clinical classification of CHD patients studied
S. no Type
of CHD
Patients
(n = 100)
Age
>1 year 1-5 years 5-10 years 10-15 years 15-20 years
1 ASD 33(33%) 2 18 8 3 2
2 VSD 32(32%) 11 17 3 1 -
3 TOF 32(32%) 12 16 3 1 -
4 SV 3(3%) 2 1 - - -
Total 100 27 52 14 5 2
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independently.
Mutation analysis
The raw sequence data were analyzed and carefully edi-
ted using the Sequence Analysis Software. The edited se-
quences were assembled with reference sequence using
DNA Star and Auto Assembler software (Applied Bio-
systems, USA). All the variant sites, compared to the ref-
erence sequence, were noted down. Genetic Association,
Hardy–Weinberg equilibrium and Chi-square test were
computed by using plink software [29]. Pathogenic
potential of identified missense mutations from CHD
patients was predicted by three different softwares. The
prediction of PolyPhen software (www.tux.embl-heidelberg.
de/ramensky/polyphen.cgi) was determined based onTable 2 Detailed description of GATA4 mutations identified in
S. no. dbSNP Exon/
intron
Coordinate
position
Nucleotide
variation
Mutation
type
1 rs61277615 Exon1 11561728 C>T 5′UTR
2 rs73203482 Intron1 11561818 G>A Splice jun
3 CM051488 Exon3 11606451 G>A Synonymo
4 rs804280 Intron5 11612698 A>C Intronic
5 rs2645457 Intron5 11614112 T>G Intronic
6 rs4841587 Intron5 11614175 G>T Intronic
7 rs4841588 Intron5 11614225 G>T Intronic
8 rs111272281 Intron5 11614264 A>del Intronic
9 rs3729853 Intron5 11614316 C>T Intronic
10 rs3729854 Intron5 11614329 C>T Intronic
11 rs142395583 Intron5 11614337 T>A Intronic
12 rs745379 Intron6 11615695 A>G Intronic
13 rs200319078 Exon7 11615835 C>A Missence
14 rs56208331 Exon7 11615928 G>A Missence
15 rs884662 Exon7 11616501 T>C 3′UTR
16 rs904018 Exon7 11616516 C>T 3′UTR
17 rs12825 Exon7 11616547 C>G 3′UTR
18 rs12458 Exon7 11617240 A>T 3′UTR
19 rs3203358 Exon7 11617505 C>G 3′UTRsequence comparison between homologous proteins. Pro-
file scores position-specific independent counts (PSIC)
were generated for the allelic variants. A PSIC score of the
variant with more than 2 indicates damaging effect, scores
between 1.5 and 2 indicate possibly damaging effects,
score 1.5 indicates that the variant is probably damaging
and score less than 1.5 indicates that the variant is benign.
PMut, software for mutation prediction, is pathogenicity
index ranging from 0 to 1. Indices greater than 0.5 indicate
pathological mutation while less than 0.5 indicate neutral.
SIFT is another sequence homology-based tool that iden-
tifies intolerant from tolerant amino acid substitutions.
This software predicts whether an amino acid substitution
at a particular position in a defined protein will have a
phenotypic effect or not. For prediction of mutation effect
on splicing of intron, we used ESE finder 3.0 [30]. Thisthis study
A.A change Frequency of mutation
ASD VSD TOF SV Control
33 32 32 3 200
- 0.06061 0.03125 0.03125 0 0.0125
ction - 0.0303 0.03125 0.04688 0 0.0075
us G214G 0.04545 0 0 0 0.0125
- 0 0.07812 0.0625 0 0.0125
0.01515 0.01562 0.01562 0 0.005
- 0.0303 0.07812 0.03125 0 0.0175
- 0.01515 0.1562 0.0625 0 0.02
- 0 0.0625 0.03125 0 0.005
- 0.0303 0.2188 0.07812 0 0.055
- 0.01515 0.04688 0.04688 0 0.01
- 0 0.01562 0.01562 0 0.0125
- 0.04545 0.1094 0.1719 0.16 0.01
P394T 0.01515 0 0 0 0.005
D425N 0 0.01562 0 0 0.0025
- 0 0.01562 0.01562 0 0.0125
- 0.04545 0.01562 0.03125 0 0.0225
- 0.01515 0.09375 0.1094 0 0.0825
- 0 0 0 0 0.01
- 0.01515 0.01562 0.01562 0 0.0125
Table 3 The allelic distributions of GATA4 polymorphism among patients and controls
dbSNP Control allele
(n = 400)
ASD allele
(n = 66)
VSD allele
(n = 64)
TOF allele
(n = 64)
Control vs. ASD Control vs. VSD Control vs. TOF
p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI)
rs61277615 5(0.0125) 4(0.06061) 2(0.03125) 2(0.03125) 0.008514 5.0968
(1.3322 -
19.4998)
0.2532 2.54849
(0.4838 -
13.4239)
0.2532 2.54849
(0.4838 -
13.4239)
rs73203482 3(0.0075) 2(0.0303) 2(0.03125) 3(0.04688) 0.09573 4.1354
(0.6777 -
25.2338)
0.08752 4.2688
(0.6992 -
26.0617)
0.009632 6.5082
(1.2843 -
32.9812)
rs804280 5(0.0125) 0 5(0.07812) 4(0.0625) - - 0.0007886 6.6949
(1.8812 -
23.8262)
0.007083 5.2667
(1.3755 -
20.1654)
rs4841587 7(0.0175) 2(0.0303) 5(0.07812) 2(0.03125) 0.4838 1.7545
(0.3565 -
8.6342)
0.004553 4.7579
(1.4622 -
15.4814)
0.459 1.8111
(0.3678 -
8.9182)
rs4841588 8(0.02) 1(0.01515) 10(0.1562) 4(0.0625) 0.7909 0.7538
(0.0927 -
6.1274)
0.0000001597 9.0741
(3.4321 -
23.9913)
0.04671 3.2667
(0.9542 -
11.1831)
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enhancers. ‘R’ packages were used for generation of plot.
Promoter mutation’s function was predicted by CONSITE
software, which finds the difference of transcription factor
binding into wild type and mutant genomic sequences.Effect of 3’ UTR region mutations on microRNA-target
interactions
The interaction of 3′UTR with microRNA was deter-
mined by a bioinformatics tool as described by Kertesz
et al. 2007 [31]. This bioinformatics tool finds microRNA-
target interactions by an energy score, ΔΔG that is equal
to the difference between the energy gained by binding of
the microRNA to the target, and dGopen, the energy re-
quired to make the target region accessible for microRNA
binding. dGduplex is the binding free energy of the
microRNA-target duplex structure in which the micro-
RNA and target are paired according to pairing con-
straints imposed by the seed. ΔΔG is an energetic score,
the lower (more negative) the value, the stronger the bind-
ing of the microRNA to the given site is expected to be.
As a rough rule of thumb, sites having ΔΔG values below
−10 are likely to be functional in endogenous microRNA
expression levels.Figure 1 DNA sequencing electropherogram showing wild type
(upper panel) and heterozygous (G→A) mutation (lower panel)
in GATA4 coding region (arrows). A. Mutation Asp425Asn,
B. Mutation Pro394Thr, C. Multiple amino acid sequence alignment
of different species shows the conservation of the mutated amino
acid residue (amino acid marked) across species.Statistical analysis
Statistical analysis was performed with Plink software
[29]. For checking markers, whether they are in hardy
Weinberg equilibrium, we used cut off p-value 0.01; and
for association analysis we used same cut off p-value
(0.01). Haploview was used to find blocks in data [32].
For finding the blocks, we considered r2 value and LOD
score. Further, we used PHASE software for making
haplotype for these blocks [33] and did association ana-
lysis with R basic packages (R version 3.0.2, 2013) [34].Results
Clinical evaluation
In the present study, we have analyzed a total of 100
CHD patients. The percentages of CHD patients belong-
ing to different categories were as follows; ASD: 33%,
VSD: 32%, TOF: 32%, and SV: 3%. Age of all CHD pa-
tients ranged from 0.35 to 10.79 years. However, max-
imum number of CHD patients taking part in this study
were of <5 years (Table 1).
Mutation analysis in GATA4 gene
We investigated the genomic DNA of CHD patients for
variations in the entire coding regions, exon-intron
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UTR) of GATA4 gene. Our analysis revealed a total of 19
mutations, of which 1 each in promoter and splicing re-
gions, 9 were in intronic regions, 3 were in exonic regions
(2 missense and one synonymous) and 5 were in 3′ UTR
(Tables 2 and 3). In silico analysis showed that one missense
mutation was conserved and predicted to be pathogenic
(Figure 1). Figure 2 shows sequence electropherogram of
two mutations, which were evidenced in promoter and
splicing regions. We evidenced the presence of homozy-
gous mutation (rs61277615) at the promoter region in two
ASD and one VSD patients, and (rs73203482) at the splice
site in one TOF patients. We have collected parent’s
samples for those patients who have either rs61277615 or
rs73203482 variations in GATA4 gene. Analysis of parents’Figure 2 DNA sequencing electropherogram of promoter mutation (r
heterozygous condition in parents and homozygous condition and thsamples revealed that parents of all the three patients had
heterozygous mutation (Figure 2).Genetic studies
To find out association between genetic markers and
CHD, we initially analyzed the effect of SNPs independ-
ently and then analyzed the haplotype level. We classi-
fied the samples on the basis of phenotype: ASD, VSD,
TOF, and SV and removed 6 markers, which were not
following Hardy-Weinberg equilibrium in ethnically
matched control samples. These markers were rs12825
(HWE p-value = 1.296e-7), rs745379 (HWE p-value =
1.894e-5), rs3203358 (HWE p-value = 9.47e-5), rs3729853
(HWE p-value = 1.855e-15), rs111272281 (HWE p-value =s61277615) and a splice junction mutation (rs73203482) showing
e patients.
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file 1: Figure S1).
Further, we performed Chi-square analysis for finding
the statistical significance and identified one 5′ UTR
(promoter region −490 to 100 bp) mutation (rs61277615,
p-value = 0.008514) in ASD. In TOF, rs73203482 (p-value =
9.6e-3, OR = 6.508) and rs804280 (p-value = 7.08e-3,
OR = 5.267) were found to be associated with the dis-
ease. In case of VSD, 3 mutations were found to have
strong association with the disease; they were rs804280Figure 3 Chi-square P-value of variations found in GATA4 of all types
C. tetralogy of fallot (TOF) and D. single ventricle (SV).(p-value = 7.9e-4, OR = 6.695), rs4841587 (p-value = 4.6e-3,
OR = 4.758) and rs4841588 (p-value = 1.6e-7, OR = 9.074).
In case of SV, we did not find any variation associated with
the CHD phenotype (Figure 3, Table 4).
In silico analysis
In coding region, we found a total of two missense mu-
tations and one synonymous mutation in CHD patients
that include Pro394Thr, Asp425Asn and Gly214Gly.
Multiple alignments of GATA4 amino acid sequencesof CHD. A. atrial septal defect (ASD), B. ventricular septal defect (VSD),
Table 4 Statistical data of GATA4 mutations and their association with ASD, VSD, TOF and SV
S. no. dbSNP Observed
heterozygosity
Expected
heterozygosity
Hardy Weinberg
P-value
P-value
ASD VSD TOF SV
1 rs61277615 0.04 0.0392 1 0.008514 0.2532 0.2532 0.7829
2 rs73203482 0.015 0.01489 1 0.09573 0.08752 0.009632 0.8314
3 CM051488 0.01 0.00995 1 0.003122 0.5708 0.5708 0.8622
4 rs804280 0.025 0.02469 1 0.3611 0.0007886 0.007083 0.7829
5 rs2645457 0.01 0.00995 1 0.3394 0.3248 0.3248 0.8622
6 rs4841587 0.025 0.03439 0.05197 0.4838 0.004553 0.459 0.7438
7 rs4841588 0.03 0.0392 0.06886 0.7909 1.597e-07 0.04671 0.7264
8 rs111272281 0 0.00995 0.002506 - - - -
9 rs3729853 0.01 0.104 1.855e-15 - - - -
10 rs3729854 0.01 0.0198 0.01502 0.7067 0.02464 0.02464 0.8056
11 rs142395583 0.025 0.02469 1 0.3611 0.8372 0.8372 0.7829
12 rs745379 0 0.0198 1.894e-05 - - - -
13 rs200319078 0.01 0.00995 1 0.3394 0.5708 0.5708 0.8622
14 rs56208331 0.005 0.004987 1 0.6843 0.1367 0.6888 0.9024
15 rs884662 0.015 0.02469 0.02497 0.3611 0.8372 0.8372 0.7829
6 rs904018 0.025 0.04399 0.002346 - - -
17 rs12825 0.075 0.1514 1.296e-07 - - -
18 rs12458 0.01 0.0198 0.01502 0.4145 0.4217 0.4217 0.0606
19 rs3203358 0.005 0.02469 9.47e-05 - - -
Bold indicates: The SNP which is not in HW-equilibrium and P-value < 0.01.
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found that asparagine at 425 position (Figure 1B) is
highly conserved during evolution. But other missense
mutation i.e., Pro394Thr is not conserved. To under-
stand the functional significance of missense mutations,
we performed bioinformatics analysis with all of identi-
fied two missense mutations using PolyPhen-2, PMut
and SIFT softwares. Results of all the three analyses
strongly indicate that Asp425Asn mutation was patho-
genic (Table 5). We analyzed functional significance of
splice junction mutation (rs73203482) by ESE finder 3.0
and found that this mutation is present near splice site
of exon 1 (ENST00000335135) and intron 1. The data
has shown the effect of binding of SFRS6, a splicing fac-
tor to the splicing region (Figure 4). This splicing factor
has a role in site selection in alternative splicing. ThisTable 5 Functional significance of mutation prediction
done by using PolyPhen-2, PMut and SIFT
P394T D425N
Name of software Prediction Score Prediction Score
PolyPhen-2 Benign 0.025 Possibly damaging 0.972
PMut Neutral 0.4499 Pathological 0.6236
SIFT Tolerated 0.55 Not Tolerated 0.24also explains that the binding of splice enhancer will be
affected in the presence of this splice mutation. We
computed the functional significance of promoter muta-
tion (promoter region −490 to 100 bp, rs61277615) and
found the transcription factor binding in the wild-type
and mutant promoter region by CONSITE software.
Our data indicated that mutant sequence strongly binds
with the transcription factor Myf1 with score of 7.360 in
comparison to wild type sequence. The score with more
than 7.0 represents the stronger binding of transcription
factor with the DNA sequence. Except Myf1, binding of
other transcription factors for both wild and mutant
sequence is the same (Additional file 1: Table S2).Haplotype analysis
Although SNPs have shown association with CHD, we
further checked whether any haplotypes also show asso-
ciation with CHD. We did not find any block of associated
markers in control samples (Figure 5A) but we found one
LD block in VSD samples (Figure 5B). We also did not
find any LD block in TOF samples (Additional file 1:
Figure S2). We found that one LD block showed strong
associations in VSD (p-value; GG: 1.906e-6, GT: 7e-4, TT:
6.01e-5) (Figure 5D, Additional file 1: Table S3). Same LD
block also showed association in 10000 permutations
Figure 4 Prediction for binding of splicing enhancer: an outcome of rs73203482 mutation.
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Additional file 1: Table S4).
Comparison of allele frequency with 1000 genome
project data
We compared the allele frequency of associated markers
with 1000 genome project data. There was no signifi-
cant difference in the allele frequency of control sam-
ples and Asian population samples of 1000 genome
project (Additional file 1: Figure S3). While we observed
differences between patient samples of VSD, TOF and
ASD in comparison to control samples. Only three
markers rs73203482, rs804280 and rs61277615 showed
difference in distribution of allele frequency between
disease samples and control samples (Figure 6).
3′ UTR mutations and their effect on microRNA-target
interactions
Exon 7 of GATA4 consists of 1,708 bp the majority
(1,525 bp) being untranslated. We identified 5 dbSNPs
in 3′-UTR region of GATA4 in the study subjects;
that include 2400T>C (rs884662), 2415T>C (rs904018),
2446C>G (rs12825), 3139A>T (rs12458) and 3404C>G
(rs3203358). We did RNA folding studies for 1500 bp of
3′-UTR of GATA4 gene that include all of the above SNPs
independently using DNA Star software, but we did not
find any change (data not shown). We then checked for
the microRNA and 3′-UTR target interaction through a
bioinformatics tool. We found interaction of 440 numbers
of microRNAs with desired UTR sequence. We found
change in free energy difference of microRNA bindingbetween wild type and mutant UTR regions. The value of
microRNA-target interactions, ΔΔG was found to be
equal to the difference between the free energy gained by
the binding of the microRNA to the target. As a rough
rule of thumb, sites having ΔΔG values below −10 were
found likely to be functional in endogenous microRNA
expression levels. While the free energy change (ΔΔG) of
wild-type UTR region was more than −10, it completely
shifted to +10 value for all 3′UTR mutant (Additional file 1:
Figure S4A and 4B).
Discussion
Genetics and environmental factors play important role
in the etiology of CHD. It has been shown that fetal
heart development is regulated by a group of highly con-
served transcription factors [35]. GATA4 is one of the
transcription factors that plays a major role in the regu-
lation of several other cardiac proteins, including atrial
natriuretic peptide, brain natriuretic peptide, cardiac
troponin C, cardiac troponin I, muscarinic acetylcholine
receptor, and slow myosin heavy chain. Small changes in
the level of GATA4 protein expression can dramatically
influence cardiac development and embryonic survival
[36]. GATA4 has been identified in familial and sporadic
cardiac septal defects. Although several studies from
different countries have established the association of
GATA4 mutation with CHD [11,37], very few studies
have been conducted in India. Therefore, we conducted
this study to find genetic link with GATA4 mutation and
correlate genotype with phenotype from subjects with
ASD, VSD, TOF and single ventricle.
Figure 5 Haplotype analysis. A. Haplotype frequency distribution of control samples. B. Linkage disequilibrium in VSD samples. C. Permutation
based analysis for haplotype association. D. Haplotype analysis of VSD samples and its allelic distributions in cases and controls.
Figure 6 Distribution of minor allele frequency of associated
GATA4 variations in ASD, VSD, TOF, SV, control sample.
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tions, out of which 2 were in promoter region, 9 were in
intronic region, 3 were in coding region (that include 2
missense mutations and one synonymous mutation) and
5 were in 3′ UTR. The GATA4 mutation frequencies
from different studies in VSD were as follows; in Americans
1.67% (2/120) [10], Chinese 1.22% (1/82) [11], Americans
0.80% (5/628) [38], Germans 16.7% (1/6) [12], and Chinese
0.48% (1/210) [8] whereas in case of TOF the frequencies
were; Americans 7.69% (2/26) [10] and Chinese 8.33% (1/
12) [11]. Since, Dravidian (Indian) population has different
genetic architecture [39,40], we observed high frequency
of rs73203482 in TOF, rs804280 in VSD, rs61277615 in
ASD in comparison to ASD, VSD, SV and control sam-
ples. The associations of rs804280 with VSD and TOF,
rs73203482 with TOF and rs61277615 with ASD are
interesting findings (Additional file 1: Figure S2). These
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Dravidian population but need to be validated in large
number of samples. GATA4 is a hyper mutable protein
according to previously published data [41]. Currently,
approximately 111 non-synonymous mutations have
been found in the GATA4 protein, including the muta-
tions identified in this study. We identified two missense
mutations i.e., Pro394Thr, and Asp425Asn and one syn-
onymous mutation Gly214Gly in the coding region of
CHD patients. The amino acid that changes due to novel
mutation is conserved throughout the species. All three
softwares PolyPhen (score 0.97), Pmut (score 0.8625)
and SIFT (score 0.27) showed that missense mutation
Asp425Asn is probably damaging, pathological and not
tolerated but other missense mutation Pro394Thr is
benign, not pathological and tolerated. Novel mutation,
Asp425Asn maps to the C-terminal domain of GATA4,
and is important for the trans-activation of downstream
targets [42].
We observed one mutation in GATA4 gene promoter
region (−490 to 100 bp). This exists in homozygous
condition in; two ASD patients, one VSD patient and
one TOF patient. Further analysis of this mutation in the
parents of the above patients revealed the presence of
heterozygous mutation. Due to high rate of consanguin-
eous marriages among South Indian populations, this
recessive mutation is much more common in the study
populations, compared to other populations. We ana-
lyzed transcription factor binding with the wild and mu-
tant type GATA4 gene and found that one transcription
factor strongly binds to the mutant but not with the wild
type. We also found one mutation near the promoter
region, specifically in the splicing region. Position of this
mutation is interesting as it may affect the splicing of
GATA4 gene. Alternative first exons are located several
kilobases upstream of the classic GATA4 transcription
initiation site suggesting that their expression is being
driven from novel upstream promoters. Some of these
first exons are conserved across species suggesting alterna-
tive promoter usage to be likely an important regulatory
mechanism for controlling the tissue- and cell-specific
expression of the GATA4 gene in humans and other
mammalian species. GATA4 first exons are used alterna-
tively and rarely in association with one another. The
rs73203482, which is present near to splicing site of exon
1 (ENST00000335135) and in intron 1 has shown to
affect binding of SFRS6, a splicing factor (Figure 4). This
splicing factor has a crucial role in site selection in
alternative splicing.
In the present study, we also observed several muta-
tions at the 3′UTR region of GATA4. We evidenced five
3′ UTR mutations from patients with ASD, VSD and
TOF. All the five mutations have been already reported
by different investigators [43]. However, Kertesz et al.experimentally showed that mutations at 3′UTR sub-
stantially reduce microRNA-mediated translational re-
pression, with effects comparable to those of mutations
that disrupt sequence complementarity. They devise a
bioinformatics tool for microRNA-target interaction that
computes the difference between the free energy gained
from the formation of the microRNA-target duplex and
the energetic cost of un-pairing the target to make it ac-
cessible to the microRNA. We used the same software to
study the functional role of the 3′UTR mutation. How-
ever, none of the study showed any functional study of
these mutations for the pathogenesis of CHD. Here, we
used bioinformatics tools to find out if these mutations
in 3′UTR cause any alteration of GATA4 function. The
3′-UTR of GATA4 is relatively long and likely contains
regulatory elements essential for the regulation and
transport of the mRNA transcript [44]. Accumulating
evidence suggests that the 3′-UTR of mRNA is involved
in the control of nuclear transport, polyadenylation sta-
tus, sub-cellular targeting as well as rates of translation
and degradation of mRNA by altering RNA secondary
structure. One of the reasons for alteration of RNA
secondary structure is due to aberrant RNA folding
[45]. To confirm the alteration of secondary structure
of RNA due to mutations in 3′ UTR, we performed
RNA folding studies, but we did not observe any
changes in RNA folding between wild type and mu-
tants (data not shown). We approached a parameter
free model for miRNA–target interactions (Pita algo-
rithm). Previously, this bioinformatics tool was used to
find the difference of miRNA–target interactions among
mutated gene [31]. Using this tool, we predicted the
thermodynamic changes during miRNA–mRNA duplex
formation. Our results showed that in wild GATA4, a
pool of microRNA binds strongly with the mRNA.
However, this binding affinity of miRNA was altered
due to the presence of 3′UTR mutations. Our study
strongly predicts that all 3′UTR GATA4 mutations
observed in CHD patients may alter the transcript level
in diseased heart and affect the embryonic development
of heart.
Conclusion
Our study identified c.620C>T mutation in GATA4 is
associated with CHD in South India. Although this mu-
tation reported in healthy individuals of other popula-
tion. For the first time we are reporting its association
with CHD in Indian population. Out of four phenotypes
we studied, genetic variations were found to be associ-
ated with ASD (rs61277615), VSD (rs804280) and TOF
(rs73203482, rs804280). c.620C>T either independently
or combinly associated with CHD. Hence GATA4 is an
important marker for CHD in India, particularly South
India.
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